Related Experiment Videos
[Clinical study on meropenem in pediatric field]
1Department of Infectious Disease, Tokyo Metropolitan Komagome Hospital.
The Japanese Journal of Antibiotics
|July 1, 1992
Summary
Meropenem (MEPM) demonstrated 100% efficacy and bacteriological eradication in pediatric infections. This parenteral carbapenem beta-lactam drug showed no observed side effects in clinical trials.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antimicrobial Therapy
Background:
- Meropenem (MEPM) is a novel parenteral carbapenem beta-lactam antibiotic.
- Pediatric infectious diseases require effective and safe treatment options.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of meropenem in pediatric patients.
- To assess the bacteriological eradication rates associated with meropenem treatment.
Main Methods:
- A total of 10 pediatric patients with various infectious diseases received meropenem (MEPM) at a dosage of 16-20 mg/kg every 8 hours via 1-hour drip infusion.
- One case of pertussis pneumonia with subsequent bronchiolitis obliterans, treated with steroids and gamma-globulin, was excluded from efficacy evaluation.
- Clinical laboratory tests were monitored in 10 patients.
Main Results:
- Meropenem (MEPM) achieved a 100% clinical efficacy rate in 9 out of 9 evaluable pediatric patients.
- A 100% bacteriological eradication rate was observed in 6 out of 6 patients.
- No adverse side effects were reported during the study.
- Mild, transient elevations in liver function tests (GOT, GPT, gamma-GTP) were noted in one patient, resolving within one week post-therapy.
Conclusions:
- Meropenem (MEPM) is a highly effective antibiotic for treating various pediatric infections.
- The drug demonstrated an excellent safety profile with no significant adverse events.
- Meropenem (MEPM) is a promising therapeutic option for pediatric infectious diseases.